Zeltherva’s (galinpepimut-S; SELLAS Life Sciences Group) larger target patient population gives it more commercial potential than other drugs being positioned towards the maintenance setting. Its biggest competition comes from oral Vidaza (azacitidine; Celgene), which is also in development for the maintenance treatment of elderly patients in complete remission regardless of mutation status, and is significantly ahead of Zeltherva in development.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.